Activated Kras gene coupled with activation of Akt and nuclear factor-kappa B (NF-jB) triggers the development of pancreatic intraepithelial neoplasia, the precursor lesion for pancreatic ductal adenocarcinoma (PDAC) in humans. Therefore, intervention at premalignant stage of disease is considered as an ideal strategy to delay the tumor development. Pancreatic malignant tumor cell lines are widely used; however, there are not relevant cell-based models representing premalignant stages of PDAC to test intervention agents. By employing a novel Kras-driven cell-based model representing premalignant and malignant stages of PDAC, we investigated the efficacy of ACTICOA-grade cocoa polyphenol (CP) as a potent chemopreventive agent under in vitro and in vivo conditions. It is noteworthy that several human intervention/clinical trials have successfully established the pharmacological benefits of cocoa-based foods. The liquid chromatography (LC)-mass spectrometry (MS)/MS data confirmed epicatechin as the major polyphenol of CP. Normal, nontumorigenic and tumorigenic pancreatic ductal epithelial (PDE) cells (exhibiting varying Kras activity) were treated with CP and epicatechin. CP and epicatechin treatments induced no effect on normal PDE cells, however, caused a decrease in the (i) proliferation, (ii) guanosine triphosphate (GTP)-bound Ras protein, (iii) Akt phosphorylation and (iv) NF-jB transcriptional activity of premalignant and malignant Krasactivated PDE cells. Further, oral administration of CP (25 mg/kg) inhibited the growth of Kras-PDE cell-originated tumors in a xenograft mouse model. LC-MS/MS analysis of the blood showed epicatechin to be bioavailable to mice after CP consumption. We suggest that (i) Kras-driven cell-based model is an excellent model for testing intervention agents and (ii) CP is a promising chemopreventive agent for inhibiting PDAC development.Pancreatic ductal adenocarcinoma (PDAC) is one of the lethal cancers found in humans. The severity and lethality of this type of cancer can be ascertained from the report published by American Cancer Society, which projected 37,660 deaths out of 44,030 new PDAC patients in year 2011 in the United States. 1 Chemotherapy and surgery are the common treatment options for PDAC, and unfortunately, both the treatment options have dismal outcome in patients. This is evident from the reports that PDAC patients have a survival rate of only 4% after surgery or chemotherapy. 1 PDAC putatively evolves through multistage neoplastic transformation process, which is reflected in a series of histologically welldefined precursor lesions termed as pancreatic intraepithelial neoplasia (PanIN). 1-3 Molecular analysis of PanIN lesions has revealed progressively accumulating genetic abnormalities involving several oncogenes. 4 Mutations of the Kras gene on chromosome 12P are one of the earliest genetic abnormalities observed during PDAC development and found in approximately 36, 44 and 87% of cancer-associated PanIN-1A, PanIN-1B and PanIN-2/3 lesions, respectively. 4 It is r...